NASDAQ:PCSA Heatwurx (PCSA) Stock Price, News & Analysis $0.21 +0.01 (+5.08%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.21 -0.01 (-2.44%) As of 10/3/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Heatwurx Stock (NASDAQ:PCSA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Heatwurx alerts:Sign Up Key Stats Today's Range$0.20▼$0.2150-Day Range$0.17▼$0.2452-Week Range$0.15▼$1.50Volume1.85 million shsAverage Volume2.57 million shsMarket Capitalization$10.73 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingHold Company Overview Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. Read More Heatwurx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScorePCSA MarketRank™: Heatwurx scored higher than 55% of companies evaluated by MarketBeat, and ranked 470th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingHeatwurx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialHeatwurx has a consensus price target of $1.00, representing about 369.0% upside from its current price of $0.21.Amount of Analyst CoverageHeatwurx has only been the subject of 3 research reports in the past 90 days.Read more about Heatwurx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Heatwurx are expected to grow in the coming year, from ($4.05) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heatwurx is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heatwurx is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeatwurx has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Heatwurx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.81% of the outstanding shares of Heatwurx have been sold short.Short Interest Ratio / Days to CoverHeatwurx has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Heatwurx has recently increased by 59.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeatwurx does not currently pay a dividend.Dividend GrowthHeatwurx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.81% of the outstanding shares of Heatwurx have been sold short.Short Interest Ratio / Days to CoverHeatwurx has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Heatwurx has recently increased by 59.81%, indicating that investor sentiment is decreasing significantly. News and Social Media1.4 / 5News Sentiment-0.50 News SentimentHeatwurx has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Heatwurx this week, compared to 0 articles on an average week.Search Interest25 people have searched for PCSA on MarketBeat in the last 30 days. This is an increase of 213% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Heatwurx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Heatwurx is held by insiders.Percentage Held by Institutions91.93% of the stock of Heatwurx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heatwurx's insider trading history. Receive PCSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heatwurx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCSA Stock News HeadlinesHeatwurx (NASDAQ:PCSA) Trading 5.1% Higher - Time to Buy?October 4 at 3:53 AM | americanbankingnews.comProcessa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury StrategiesAugust 7, 2025 | globenewswire.comBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.October 5 at 2:00 AM | Crypto 101 Media (Ad)Processa Pharmaceuticals Provides Portfolio and Business UpdateJuly 1, 2025 | globenewswire.comProcessa Pares Gains on Equity Offer NewsJune 17, 2025 | marketwatch.comProcessa Pharmaceuticals Announces Pricing of $7 Million Public OfferingJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug CandidateJune 17, 2025 | globenewswire.comProcessa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International ConventionJune 15, 2025 | nasdaq.comSee More Headlines PCSA Stock Analysis - Frequently Asked Questions How have PCSA shares performed this year? Heatwurx's stock was trading at $0.8838 on January 1st, 2025. Since then, PCSA stock has decreased by 75.9% and is now trading at $0.2132. How were Heatwurx's earnings last quarter? Heatwurx Inc. (NASDAQ:PCSA) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.02. When did Heatwurx's stock split? Shares of Heatwurx reverse split before market open on Monday, January 22nd 2024.The 1-20 reverse split was announced on Monday, January 22nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Heatwurx? Shares of PCSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Heatwurx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heatwurx investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and Builders FirstSource (BLDR). Company Calendar Last Earnings8/07/2025Today10/05/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PCSA CIK1533743 Webwww.processapharmaceuticals.com Phone(443) 776-3133Fax443-288-4420Employees20Year Founded2017Price Target and Rating Average Price Target for Heatwurx$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside+369.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-342.36% Return on Assets-243.48% Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book0.46Miscellaneous Outstanding Shares50,350,000Free Float49,141,000Market Cap$10.73 million OptionableNot Optionable Beta1.53 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:PCSA) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heatwurx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heatwurx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.